Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14478517 | 1.00 | LMNA (0.46) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL12507403 | 0.86 | LMNA (0.46) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL18089526 | 0.85 | TDP1 (0.38) | LMNAL3MBTL1TDP1KDM4ETSHR | |
| SCHEMBL14294311 | 0.85 | TDP1 (0.38) | LMNAL3MBTL1TDP1KDM4ETSHR | |
| SCHEMBL14618765 | 0.83 | TDP1 (0.36) | TDP1TSHR | |
| SCHEMBL14747616 | 0.83 | TDP1 (0.36) | TDP1TSHR | |
| SCHEMBL27368252 | 0.82 | LMNA (0.42) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL14726547 | 0.82 | LMNA (0.42) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL14619378 | 0.82 | LMNA (0.42) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL14619515 | 0.82 | LMNA (0.42) | LMNAL3MBTL1TDP1KDM4EPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120190013-A1 | HYDROLASE ENZYME SUBSTRATES AND USES THEREOF | DIAZYME LABORATORIES, INC. | 2012-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190013-A1 | HYDROLASE ENZYME SUBSTRATES AND USES THEREOF | DNPH1, HDHD5, ENGASE | LMNA 3121/4885L3MBTL1 2188/4885TDP1 434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.